遠大醫藥(00512.HK)獲眼表疾病新藥生產及商業化權利
遠大醫藥(00512.HK)公布,與撥雲製藥訂立產品授權協議,獲得撥雲製藥開發的全球創新產品CBT-001包括翼狀(贅)肉(一種常見的慢性炎症增生性眼表疾病)在內的全部適應症在中國、香港、澳門及台灣地區的獨家生產及商業化權利。
根據約定,集團將按產品的註冊開發進度分階段向撥雲廣州支付首付款和里程碑付款不超過7,450萬人民幣,並按CBT-001的年度銷售金額淨額支付若干比例的權利金。
同時,集團將以代價563萬美元認購撥雲開曼擴大後股本6.5%,取得撥雲開曼一個董事席位。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.